A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.
Antineoplastic Agents
/ pharmacology
Biomarkers
CD8-Positive T-Lymphocytes
Cell Line, Tumor
Humans
Interleukin-2
/ administration & dosage
Interleukin-2 Receptor alpha Subunit
/ metabolism
Neoplasms
/ drug therapy
Polyethylene Glycols
/ administration & dosage
Signal Transduction
/ drug effects
Treatment Outcome
Tumor Microenvironment
/ drug effects
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
22
12
2018
revised:
25
03
2019
accepted:
09
04
2019
pubmed:
17
4
2019
medline:
9
7
2020
entrez:
17
4
2019
Statut:
ppublish
Résumé
NKTR-214 (bempegaldesleukin) is a novel IL2 pathway agonist, designed to provide sustained signaling through heterodimeric IL2 receptor βγ to drive increased proliferation and activation of CD8
Identifiants
pubmed: 30988166
pii: 2159-8290.CD-18-1495
doi: 10.1158/2159-8290.CD-18-1495
doi:
Substances chimiques
Antineoplastic Agents
0
Biomarkers
0
IL2RA protein, human
0
Interleukin-2
0
Interleukin-2 Receptor alpha Subunit
0
Polyethylene Glycols
3WJQ0SDW1A
bempegaldesleukin
BNO1JG5MZC
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
711-721Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
©2019 American Association for Cancer Research.